发明名称 Therapeutic systems
摘要 A compound comprising a target cell-specific portion and human NAD(P)H:quinone reductase 2 (NQO2) or a variant or fragment or fusion or derivative thereof which has substantially the same activity as NQO2 towards a given prodrug, or a polynucleotide encoding said NQO2 or said variant or fragment or fusion or derivative. A recombinant polynucleotide comprising a target cell-specific promoter operably linked to a polynucleotide encoding human NAD(P)H:quinone reductase 2 (NQO2) or a variant or fragment or fusion or derivative thereof which has substantially the same activity as NQO2 towards a given prodrug. The compounds and polynucleotides are useful in a method of treating a patient in conjunction with a suitable prodrug. A method of treating a human patient with a target cell to be destroyed wherein the target cell expresses NQO2 the method comprising administering to the patient a prodrug which is converted to a substantially cytotoxic drug by the action of NQO2 and nicotinamide riboside (reduced) (NRH) or an analogue thereof which can pass reducing equivalents to NQO2.
申请公布号 US6867231(B1) 申请公布日期 2005.03.15
申请号 US20000445865 申请日期 2000.02.11
申请人 ENZACTA R & D LIMITED 发明人 BURKE PHILIP JOHN;KNOX RICHARD JOHN
分类号 C12N15/09;A61K31/455;A61K31/711;A61K45/00;A61K47/22;A61K47/48;A61K48/00;A61P35/00;(IPC1-7):A01N47/10;A01N43/00;A61K31/785 主分类号 C12N15/09
代理机构 代理人
主权项
地址